Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 19 August 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1681008

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas

This article is a correction to:

  1. Triple Therapy Revolutionizes Treatment Paradigms for Previously Untreatable HCC Complicated by High-Flow Hepatic Arteriovenous Fistulas

    1. Read original article
Jinpeng Li,&#x;Jinpeng Li1,2†Yuanming Li&#x;Yuanming Li3†Jingtao Zhong&#x;Jingtao Zhong4†Jiasheng DuJiasheng Du5Jiao ChenJiao Chen2Jutian ShiJutian Shi2Lujun Zhao*&#x;Lujun Zhao1*†Jinlong Song*&#x;Jinlong Song2*†
  • 1Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
  • 2Department of Interventional Therapy I, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
  • 3Interventional Vascular Department, Laizhou Hospital of Traditional Chinese Medicine, Laizhou, Shandong, China
  • 4Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
  • 5Graduate Department of Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

A Correction on
Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas

By Li J, Li Y, Zhong J, Du J, Chen J, Shi J, Zhao L and Song J (2025) Front. Immunol. 16:1643290. doi: 10.3389/fimmu.2025.1643290

Author “Lujun Zhao” was erroneously spelled as “Luzhun Zhao”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, high-flow hepatic arteriovenous fistula, hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, tyrosine kinase inhibitors

Citation: Li J, Li Y, Zhong J, Du J, Chen J, Shi J, Zhao L and Song J (2025) Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas. Front. Immunol. 16:1681008. doi: 10.3389/fimmu.2025.1681008

Received: 06 August 2025; Accepted: 07 August 2025;
Published: 19 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Li, Li, Zhong, Du, Chen, Shi, Zhao and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lujun Zhao, emhhb2x1anVuQHRqbXVjaC5jb20=; Jinlong Song, amxzNzI4NkAxNjMuY29t

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.